Arizona will receive close to $2 million, as part of $100 million multi-state settlement with Abbott Laboratories. From Phoenix, KJZZ’s Mark Brodie has more.

MARK BRODIE: Forty-five states and the federal government alleged Abbott marketed its drug, Depakote, for uses not approved by the Food and Drug Administration. The medication is used to treat seizure disorders and bipolar disorder. But, the attorneys general and federal government alleged the company was also marketing the drug to be used for autism, schizophrenia and agitated dementia. In a statement, Abbott Laboratories says it’s agreed to plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act for misbranding, and is pleased to resolve the matter. The settlement also prohibits Abbott from making false or misleading claims about Depakote or marketing it for off-label uses.